• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227
• 3. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 4. Aggregation, pretransitional behavior, and optical properties in the isotropic phase of lyotropic chromonic liquid crystals studied in high magnetic fields
  Tanya Ostapenko,Peter J. Collings,Samuel N. Sprunt,J. T. Gleeson Soft Matter, 2013,9, 9487-9498
• 5. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Alkaloids and derivatives
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives

Recent Advances in the Study of 3-(2-piperidyl)propanoic acid (CAS 4088-33-9) in Chemical Biology and Pharmaceutical Research

3-(2-piperidyl)propanoic acid (CAS 4088-33-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications as a key intermediate in drug synthesis and its potential biological activities. This research briefing aims to provide an overview of the latest findings related to this compound, focusing on its synthesis, pharmacological properties, and emerging therapeutic applications.

Recent studies have highlighted the compound's role as a precursor in the synthesis of various pharmacologically active molecules. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its utility in creating novel GABA receptor modulators, showing promising results in preclinical models of neurological disorders. The structural flexibility of 3-(2-piperidyl)propanoic acid allows for diverse modifications, making it particularly valuable in medicinal chemistry applications.

In terms of biological activity, new research has uncovered potential anti-inflammatory properties of derivatives based on this scaffold. A study published in Bioorganic & Medicinal Chemistry Letters (2024) reported that certain 3-(2-piperidyl)propanoic acid derivatives exhibited significant inhibition of pro-inflammatory cytokines in vitro, suggesting potential applications in treating chronic inflammatory conditions. These findings open new avenues for structure-activity relationship studies and drug development.

The compound's pharmacokinetic properties have also been the subject of recent investigation. Advanced analytical techniques, including LC-MS/MS and NMR spectroscopy, have been employed to study its metabolic stability and distribution patterns. These studies, published in Drug Metabolism and Disposition (2023), provide valuable insights for optimizing drug formulations containing this structural motif.

From a synthetic chemistry perspective, novel green chemistry approaches to producing 3-(2-piperidyl)propanoic acid have been developed. A 2024 paper in Organic Process Research & Development described an environmentally friendly catalytic process that improves yield while reducing hazardous byproducts. This advancement addresses both economic and sustainability concerns in pharmaceutical manufacturing.

Looking forward, several research groups are exploring the incorporation of 3-(2-piperidyl)propanoic acid into more complex drug delivery systems. Preliminary results from these investigations suggest potential applications in targeted therapy and controlled release formulations. As these studies progress, we anticipate seeing more clinical applications emerging for compounds based on this important chemical scaffold.

• 69222-96-4(2-(2R)-piperidin-2-ylacetic acid)
• 41601-13-2(Nonanoic acid, compd. with N-cyclohexylcyclohexanamine (1:1))
• 19832-04-3(2-Piperidylacetic Acid)
• 61042-49-7(Heptanoic acid, 7-[(1-methylnonyl)amino]-, hydrochloride)
• 860764-88-1(2-Piperidineaceticacid, 6-methyl-)
• 18325-18-3(3-(Pyrrolidin-2-yl)propanoic acid)
• 887587-19-1(2-(2-methylpiperidin-4-yl)acetic acid)
• 64625-19-0(2-(2S)-piperidin-2-ylacetic acid)
• 63987-69-9(4-(piperidin-2-yl)butanoic acid hydrochloride)
• 99310-43-7(3-(2-piperidyl)propanoic acid;hydrochloride)